Amarin Corporation plc

NASDAQ:AMRN ISIN:US0231112063

Amarin Corporation plc. (NASDAQ:AMRN) is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa(R) (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription. For more information about Vascepa(R) visit http://www.vascepa.com

  

News

VIDEO: Matinas Biopharma's (NYSE:MTNB) Jerome Jabbour and Prescription Omega-3 for Potential Cardio-Vascular Disease Remediation

🕔9/26/2018 3:01:22 PM 4948

Join Ellis Martin for a conversation with Jerome Jabbour, CEO and Director of Matinas Biopharma (NYSEAMERICAN:MTNB).

Read Full Article
###

565 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 44) (Last 30 Days: 178) (Since Published: 565) 

Markets NASDAQ:AMRN

Company Data

    Headquarters
  • 2 PEMBROKE HOUSE, UPPER PEMBROKE
    STREET 28-32
    DUBLIN 2
    IRELAND
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.amarincorp.com
  • E:
  • investor.relations@amarincorp.com

Social Media